Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

  • Plummer R
  • Attard G
  • Pacey S
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Purpose:To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of lexatumumab (HGS-ETR2), a fully human agonistic monoclonal antibody which targets and activates the tumor necrosis factor ^ related apoptosis-inducing ligand receptor 2 (TRAIL-R2) in patients with advanced solid malignancies. Experimental Design: In this phase 1, open label study, patients with advanced solid malignan-cies were treated with escalating doses of lexatumumab administered i.v. over 30 to120 min every 21days. A cohort of four patients, which could be expanded to six patients, was studied at each dose level. The dose-limiting toxicity (DLT) dose was defined as the dose at which the incidence of DLT in the first two cycles was z33%.The maximum tolerated dose was defined as the highest dose at which

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • Ruth Plummer

  • Gerhardt Attard

  • Simon Pacey

  • Louise Li

  • Albiruni Razak

  • Rebecca Perrett

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free